Optum Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Eden Prairie MN United States (1993)
Status: No NME R&D (1993)

Organization Overview

First Clinical Trial
2008
NCT00550797
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

i3 Drug Safety | i3 Research | i3 Statprobe | Ingenix | Optum, Inc. | OptumInsight | OPTUM Insight

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Amyloidosis (Phase 3)

Asthma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Cognitive Dysfunction (Phase 3)

Delirium (Phase 2)

Diabetes Mellitus (Phase 2)

Heart Failure (Phase 2)

Hip Fractures (Phase 2)

Hydrocephalus (Phase 3)

Hydrocephalus, Normal Pressure (Phase 3)

Kidney Diseases (Phase 4)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 14